The Flow Cytometry (FC) Core offers centralized expertise and instrumentation in Flow Cytometry and Cell Sorting to investigators of the Cancer Center. The extensive user support includes a) assisting in planning, executing, and analyzing Flow Cytometry experiments; b) daily instrument setup, maintenance, quality control and performance monitoring; c) facilitating instrument access through implementation of adequate polices with an easy and reliable scheduling system; d) offering several software site licenses for high-end Flow data analysis; and e) extensive training and education options. Instrument based-services include operator-assisted cell sorting in five multiparametric FACSAria high-speed cell sorters, user-operated cell sorting in two multiparametric FACSAria cell sorters, and user-operated analysis in five high-end multiparametric analyzers (two LSRII and three LSR Fortessa) and a four-parameter FACSCalibur. Altogether, the availability of high-end instrumentation and highly qualified staff with experience provide investigators of the Center access to highly purified cell populations, and the possibility to characterize cell subsets involved in the processes of tumor development, which can ultimately lead to improved cancer diagnosis and therapy. The services provided by the FC Core have supported 239 investigators from over 140 laboratories in the last year. During the past grant period the efforts of the Core contributed to 843 publications of researchers from the 10 Programs. As an illustration of this support, a recent collaborative study among the laboratories of Drs. Sadelain (ET,CR), van den Brink (IT,CR), and Schietinger (IT) was facilitated by the Core?s expertise and instrumentation provided to analyze immunophenotypic markers in T cells, phopho-flow to analyze T cell signal transduction pathways, as well as state-of-the-art sorting services to isolate GFP-labeled CAR T cells from mouse transplants that were subsequently subjected to transcriptome profiling. The resulting publication of this study provides insight into mechanisms of allogeneic CD19 CAR T cells promoting anti-tumor activity in lymphomas.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084812
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Ghaznavi, Sana A; Ganly, Ian; Shaha, Ashok R et al. (2018) Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer. Thyroid 28:1293-1300
Hernandez, Jonathan M; Beylergil, Volkan; Goldman, Debra A et al. (2018) Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. Ann Surg 267:898-904
Juluru, Krishna; Elnajjar, Pierre; Shih, Hao-Hsin et al. (2018) An Informatics Approach to Facilitate Clinical Management of Patients With Retrievable Inferior Vena Cava Filters. AJR Am J Roentgenol 211:W178-W184
Li, Guang; Sun, August; Nie, Xingyu et al. (2018) Introduction of a pseudo demons force to enhance deformation range for robust reconstruction of super-resolution time-resolved 4DMRI. Med Phys 45:5197-5207
Kishinevsky, Sarah; Wang, Tai; Rodina, Anna et al. (2018) HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons. Nat Commun 9:4345
Attiyeh, Marc A; Chakraborty, Jayasree; Gazit, Lior et al. (2018) Preoperative risk prediction for intraductal papillary mucinous neoplasms by quantitative CT image analysis. HPB (Oxford) :
Liu, Dazhi; Offin, Michael; Harnicar, Stephen et al. (2018) Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag 14:1247-1252
Corso, Giovanni; Veronesi, Paolo; Sacchini, Virgilio et al. (2018) Prognosis and outcome in CDH1-mutant lobular breast cancer. Eur J Cancer Prev 27:237-238
Choueiri, Toni K; Hessel, Colin; Halabi, Susan et al. (2018) Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eu Eur J Cancer 103:287
Sanabria, Alvaro; Kowalski, Luiz P; Shah, Jatin P et al. (2018) Growing incidence of thyroid carcinoma in recent years: Factors underlying overdiagnosis. Head Neck 40:855-866

Showing the most recent 10 out of 8799 publications